Sequenom in Discussions with FDA on Premarket Application for Sequencing-Based Trisomy 21 Test | GenomeWeb

By Monica Heger

This story was originally posted March 9.

Sequenom is on track to launch its sequencing-based prenatal diagnostic test for trisomy 21, called SensiGene T21, as a laboratory-developed test by the end of 2011 or early 2012 and plans to file for premarket approval of the test with the US Food and Drug Administration by late 2012 or early 2013.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."